[1] |
Kaplan AP. Treatment of chronic spontaneous urticaria[J]. Allergy Asthma Immunol Res, 2012,4(6):326⁃331. doi: 10.4168/aair.2012. 4.6.326.<br />
|
[2] |
Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor[J]. J Biol Chem, 1994,269(42):26368⁃26373.<br />
|
[3] |
Kaplan AP. Biologic agents in the treatment of urticaria[J]. Curr Allergy Asthma Rep, 2012,12(4):288⁃291. doi: 10.1007/s11882⁃012⁃0268⁃1.<br />
|
[4] |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update[J]. Allergy, 2014,69(7):868⁃887. doi: 10.1111/all.12313.<br />
|
[5] |
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[EB/OL]. http://training.cochrane.org./handbook.<br />
|
[6] |
Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase[J]. J Allergy Clin Immunol, 2011,128(1):202⁃209.e5. doi: 10.1016/j.jaci.2011.04.038.<br />
|
[7] |
Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo⁃controlled, dose⁃ranging study of single⁃dose omalizumab in patients with H1⁃antihistamine⁃refractory chronic idiopathic urticaria[J]. J Allergy Clin Immunol, 2011,128(3):567⁃573.e1. doi: 10.1016/j.jaci.2011.06.010.<br />
|
[8] |
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy[J]. J Allergy Clin Immunol, 2013,132(1):101⁃109. doi: 10.1016/j.jaci.2013.05.013.<br />
|
[9] |
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa1215372.<br />
|
[10] |
Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306.<br />
|
[11] |
Study of efficacy and safety of omalizumab in refractory chronic spontaneous urticaria patients[DB/OL]. National Library of Medicine(US). 2014⁃12⁃31(2016⁃09⁃21). https://www.clinicaltrials.gov/ct2/show/study/NCT02329223.<br />
|
[12] |
Mode of action study of omalizumab in patients with chronic idiopathic urticaria (CIU) who fail to respond to antihistamine treatment[DB/OL]. National Library of Medicine(US). 2012⁃05⁃16(2015⁃03⁃31). https://www.clinicaltrials.gov/ct2/show/study/NCT01599637.<br />
|
[13] |
Młynek A, Zalewska⁃Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria?[J]. Allergy, 2008,63(6):777⁃780. doi: 10.1111/j.1398⁃9995.2008.01726.x.<br />
|
[14] |
Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU⁃QoL)[J]. Allergy, 2005,60(8):1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x.<br />
|
[15] |
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)⁃⁃a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994,19(3):210⁃216.<br />
|
[16] |
Romano C, Sellitto A, De Fanis U, et al. Maintenance of remission with low⁃dose omalizumab in long⁃lasting, refractory chronic urticaria[J]. Ann Allergy Asthma Immunol, 2010,104(1):95⁃97. doi: 10.1016/j.anai.2009.11.017.<br />
|
[17] |
Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti⁃IgE antibody[J]. Clin Rev Allergy Immunol, 2005,29(1):31⁃48.<br />
|
[18] |
Iemoli E, Piconi S, Fusi A, et al. Immunological effects of omalizumab in chronic urticaria: a case report[J]. J Investig Allergol Clin Immunol, 2010,20(3):252⁃254.<br />
|